Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertram Pitt

Showing results (421-430 of 688) with videos related to

Pageof 69
Sort By:
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 22, 2022
Kidney outcomes with finerenone: an analysis from the FIGARO-DKD studyLuis M Ruilope, Bertram Pitt, Stefan D Anker, et al.
European Journal of Heart Failure|March 3, 2022
Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trialGerasimos Filippatos, Bertram Pitt, Rajiv Agarwal, et al.
Circulation|June 23, 2017
Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist)Sheila M Hegde, Brian Claggett, Amil M Shah, et al.
Circulation. Heart Failure|December 4, 2013
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)Patrick Rossignol, Daniela Dobre, John J V McMurray, et al.
American Heart Journal|October 8, 2013
Learning from recent trials and shaping the future of acute heart failure trialsRobert J Mentz, Gary Michael Felker, Tariq Ahmad, et al.
JACC. Heart Failure|September 13, 2020
Associations Between Depressive Symptoms and HFpEF-Related OutcomesAlvin Chandra, Michael A D Alcala, Brian Claggett, et al.
JACC. Basic to Translational Science|March 21, 2026
Unmasking Hormonal Mechanisms of Hypertension in ObesityStéfanie Parisien-La Salle, Cheng-Hsuan Tsai, Andrew J Newman, et al.
Heart (British Cardiac Society)|April 27, 2018
Individual participant data analysis of two trials on aldosterone blockade in myocardial infarctionFarzin Beygui, Eric Van Belle, Patrick Ecollan, et al.
American Journal of Nephrology|September 14, 2023
Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD post hoc AnalysisDaisuke Koya, Stefan D Anker, Luis M Ruilope, et al.
Diabetes, Obesity & Metabolism|November 4, 2022
Effect of finerenone on the occurrence of vision-threatening complications in patients with non-proliferative diabetic retinopathy: Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR)Peter Rossing, Justus G Garweg, Stefan D Anker, et al.
Pageof 69

Showing results (421-430 of 688) with videos related to

Sort By:
Pageof 69
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 22, 2022
Kidney outcomes with finerenone: an analysis from the FIGARO-DKD studyLuis M Ruilope, Bertram Pitt, Stefan D Anker, et al.
European Journal of Heart Failure|March 3, 2022
Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trialGerasimos Filippatos, Bertram Pitt, Rajiv Agarwal, et al.
Circulation|June 23, 2017
Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist)Sheila M Hegde, Brian Claggett, Amil M Shah, et al.
Circulation. Heart Failure|December 4, 2013
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)Patrick Rossignol, Daniela Dobre, John J V McMurray, et al.
American Heart Journal|October 8, 2013
Learning from recent trials and shaping the future of acute heart failure trialsRobert J Mentz, Gary Michael Felker, Tariq Ahmad, et al.
JACC. Heart Failure|September 13, 2020
Associations Between Depressive Symptoms and HFpEF-Related OutcomesAlvin Chandra, Michael A D Alcala, Brian Claggett, et al.
JACC. Basic to Translational Science|March 21, 2026
Unmasking Hormonal Mechanisms of Hypertension in ObesityStéfanie Parisien-La Salle, Cheng-Hsuan Tsai, Andrew J Newman, et al.
Heart (British Cardiac Society)|April 27, 2018
Individual participant data analysis of two trials on aldosterone blockade in myocardial infarctionFarzin Beygui, Eric Van Belle, Patrick Ecollan, et al.
American Journal of Nephrology|September 14, 2023
Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD post hoc AnalysisDaisuke Koya, Stefan D Anker, Luis M Ruilope, et al.
Diabetes, Obesity & Metabolism|November 4, 2022
Effect of finerenone on the occurrence of vision-threatening complications in patients with non-proliferative diabetic retinopathy: Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR)Peter Rossing, Justus G Garweg, Stefan D Anker, et al.
Pageof 69